drugset / Trial / NCT02194270

Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers

NCT02194270

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the relative bioavailability of ambroxol hydrochloride soft pastilles 15 mg vs. ambroxol hydrochloride (HCL) 15 mg of syrup (15mg/5mL, Reference I) and ambroxol hydrochloride 15 mg of syrup (30mg/5mL, Reference II) in a fasted state

Timeline

Start
2004-09
Primary completion
2005-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambroxol Small molecule 15 mg Oral

Indications

No indication recorded.